May 31, 2026 — RNews

#immunotherapy — Sunday, May 31, 2026 (2 items)

hot top new

0		💬 0	MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. (nature.com)	Wermke M … Reinhardt C Nature Medicine 2026-05-31	#cancer #clinical trial #immunotherapy #toxicity #tcr
0		💬 0	Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. (linkinghub.elsevier.com)	Lu S … Xia MY The Lancet 2026-05-31	#cancer #clinical trial #immunotherapy #chemotherapy #nsclc